Tags : Y-mAbs

Weekly Snapshot

PharmaShots Weekly Snapshot (Nov 23 – 27, 2020)

Merck Collaborates with Siemens for the Digitalization of Production Published: Nov 26, 2020 | Tags: Agreement, Collaborative, Digitalization, Merck, Siemens, Sign CoSara Receives CDSCO’s Approval for its Saragene COVID-19 2-Gene Multiplex Test Published: Nov 26, 2020 | Tags: approval, CDSCO, Co-Diagnostics JV CoSara, COVID-19 2-gene multiplex RT-PCR, India, Manufacture, receives, Saragene, Sell, Test PostEra Collaborates […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Jun 01-05, 2020)

1. Novartis Reports Results of Enerzair Breezhaler (QVM149) in P-IIIb ARGON Study to Treat Uncontrolled Asthma Published: Jun 04, 2020 | Tags: Novartis, Reports, Enerzair Breezhaler, QVM149, P-IIIb, ARGON Study, Treat, Uncontrolled Asthma 2. Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals Published: Jun 04, 2020 | Tags: Melinta Therapeutics, Acquire, Tetraphase Pharmaceuticals 3. AstraZeneca Signs an Agreement with […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (March 30 – April 03, 2020)

1. Sorrento Initiates the Next Phase of its Collaboration with Celularity Published: Apr 02, 2020 | Tags: Sorrento, Initiates, Next Phase, Collaboration, Celularity 2.  Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic Published: Apr 03, 2020 | Tags: Celltrion, Enters, Next Phase, Development, Antiviral Therapy, Combat, COVID-19 Pandemic 3. […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (December 02-06, 2019)

1.  Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major Depressive Disorders  2. UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-To-Severe Chronic Plaque Psoriasis Published: Dec 06, 2019 | Tags: UCB, […]Read More

Regulatory

Y-mAbs Reports EMA’s Acceptance of Pediatric Investigation Plan for Omburtamab

Shots: EMA has agreed to the Y-mAbs’ proposed Pediatric Investigation Plan (“PIP”) for Omburtamab which follows EMA’s Pediatric Committee’s positive opinion The PIP approval allows Y-mAbs to file MAA of Omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma with its anticipated submission in H2’20 Omburtamab is mAb targeting B7-H3, being developed […]Read More